1/13/2016 - $0.95 (low) 5/2/2016 - $1.87 (high
Post# of 72440
(Total Views: 169)
Posted On: 04/20/2017 4:24:06 PM
1/13/2016 - $0.95 (low)
5/2/2016 - $1.87 (high)
2016 Potential Catalyst
1. P: Phase 2a top-line data - Q2
4/20/2017 - $0.79 (low)
2017 high - ?
2017 Potential Catalysts
1. B-UP: cohort 3 data - Q2
2. P: 6-week interim data - Q2
3. B-OM: interim data -Q3
4. P: Phase 2b top-line data - Q3
5. B-OM: top-line data - Q4
6. K-OC: top-line data - Q4
4 for 4 in clinical trials (100% success rate)
Kevetrin
Positive primary endpoint and p21 data (Phase 1)
5/2/2016 - $1.87 (high)
2016 Potential Catalyst
1. P: Phase 2a top-line data - Q2
4/20/2017 - $0.79 (low)
2017 high - ?
2017 Potential Catalysts
1. B-UP: cohort 3 data - Q2
2. P: 6-week interim data - Q2
3. B-OM: interim data -Q3
4. P: Phase 2b top-line data - Q3
5. B-OM: top-line data - Q4
6. K-OC: top-line data - Q4
4 for 4 in clinical trials (100% success rate)
Kevetrin
Positive primary endpoint and p21 data (Phase 1)
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼